Dermatology Department, Centre of Postgraduate Medical Education/Central Clinical Hospital MSWiA, Warsaw, Poland.
Faculty of Medicine, The Medical University of Warsaw, Warsaw, Poland.
J Dermatolog Treat. 2022 May;33(3):1581-1584. doi: 10.1080/09546634.2020.1861177. Epub 2020 Dec 22.
Biologics are used for the treatment of patients with moderate to severe psoriasis. According to the recommendations of major global dermatological associations, patients who had not reported clinical symptoms or close contact with a confirmed/probable COVID-19 case in the last 14 days can continue biologic therapy.
The aim of our study was to determine the prevalence of SARS-CoV-2 infection, its clinical manifestations and the influence of COVID-19 on the course of the underlying disease in patients with moderate to severe psoriasis and aggressive psoriatic arthritis undergoing biologic therapy.
All 61 patients with moderate to severe psoriasis treated with biologics in the Dermatology Department of Central Clinical Hospital of Ministry of the Interior and Administration in Warsaw were enrolled into the study. Firstly, the medical histories of these patients were assessed for occurrence of severe adverse events, COVID-19 symptoms and deaths. Afterwards, the prevalence of serum anti-SARS-CoV-2 antibodies, and severity of COVID-19 were assessed.
Ten patients in the study group have developed anti-SARS-CoV-2 antibodies. One patient presented with mild COVID-19 symptoms.
While our study had a small sample size, ongoing biologic treatment in psoriasis was not associated with severe form of COVID-19.
生物制剂被用于治疗中重度银屑病患者。根据主要全球皮肤科协会的建议，如果患者在过去 14 天内没有报告临床症状或与确诊/疑似 COVID-19 病例密切接触，可以继续接受生物治疗。
我们的研究旨在确定中重度银屑病和侵袭性银屑病关节炎患者接受生物治疗期间 SARS-CoV-2 感染的流行情况、其临床表现以及 COVID-19 对基础疾病病程的影响。
在华沙内政和行政部中央临床医院皮肤科，纳入了所有 61 名接受生物制剂治疗的中重度银屑病患者。首先，评估了这些患者发生严重不良事件、COVID-19 症状和死亡的病史。然后，评估了血清抗 SARS-CoV-2 抗体的流行情况和 COVID-19 的严重程度。
研究组中有 10 名患者产生了抗 SARS-CoV-2 抗体。1 名患者出现轻度 COVID-19 症状。
尽管我们的研究样本量较小，但生物制剂治疗银屑病与 COVID-19 的严重形式无关。
